Renalytix PLC (RENX), the AI-enabled kidney disease diagnostics company, has disclosed that UBS AG, acting under UBS Group AG's Investment Bank and Global Wealth Management division, crossed the 5% major shareholding threshold on 11 November 2026. The TR-1 regulatory notification, issued on 12 November 2026, confirms UBS AG now holds 34,383,571 voting rights, representing 5.128360% of Renalytix's total voting rights. The disclosure is a mandatory regulatory requirement under the Financial Conduct Authority's Disclosure and Transparency Rules, triggered when a holder crosses a notifiable threshold in a UK-listed issuer. Investors may be watching the development as a signal of significant institutional positioning in the company.

Key Points

  • Renalytix PLC (RENX) — AI-enabled kidney diagnostics company listed in the UK
  • UBS AG has crossed the 5% voting rights threshold, triggering a mandatory major holdings notification under DTR5
  • UBS AG holds 34,383,571 shares, equating to 5.128360% of voting rights, up from a previously notified position of 0.000000%
  • Investors should watch whether UBS AG increases or reduces its position in subsequent TR-1 filings

UBS AG Acquires 34.38 Million Renalytix Shares, Crossing the 5% Regulatory Threshold

The TR-1 form confirms that UBS AG, registered in London, United Kingdom, acquired voting rights attached to ordinary shares in Renalytix PLC carrying ISIN code GB00BYWL4Y04. The threshold was crossed on 11 November 2026, with the issuer notified the following day, 12 November 2026. The notification states the acquisition was made directly under DTR5.1, with no indirect holdings and no financial instruments such as options or convertibles disclosed. The previous notified position stood at 0.000000%, meaning this represents an entirely new major stake, not an increment to an existing disclosed holding.

UBS Group AG Structure and Chain of Control Behind the Renalytix Stake

The announcement identifies UBS Group AG, headquartered in Zürich, Switzerland, as the entity subject to the notification obligation, with UBS AG as the direct shareholder holding the 5.128360% stake. The notification confirms that UBS Group AG is not controlled by any natural person or legal entity, and the full chain of controlled undertakings runs from UBS Group AG through to UBS AG, which directly holds the 34,383,571 voting rights. No proxy voting arrangements are disclosed, and no financial instruments with voting rights attached are reported under either the DTR5.3.1R(1)(a) or DTR5.3.1R(1)(b) categories.

Renalytix PLC's AI-Driven Kidney Diagnostics Business and Investor Context

Renalytix PLC develops and commercialises artificial intelligence-enabled diagnostic tools focused on kidney disease, with its KidneyIntelX platform designed to support early-stage chronic kidney disease management. The company operates across both UK and US markets. The entry of a major global financial institution such as UBS AG at the 5% level may attract attention from existing and prospective investors, though the announcement does not indicate the commercial rationale for the acquisition or whether the position reflects asset management, trading, or strategic interest activity. The company did not disclose this figure in the announcement regarding any associated transaction value.